Cardiosense is building a non-invasive monitoring platform which provides insight into early signs of cardiac decline, enabling proactive optimized care.
Chicago
Joined June 2021
- Tweets69
- Following30
- Followers161
- Likes32
That's a wrap on HFSA 🎉 We were genuinely inspired by the excitement from HF specialists for non-invasive cardiac filling pressure, and the strong interest and stream of questions about CardioTag™ at 'Choosing the Right Remote Monitoring Tool.' 🫀
That's a wrap on ACEP26 🎉
Great to see so much enthusiasm for non-invasive cardiac filling pressures in emergency triage and workflows.
📍 Next stop: HFSA Devices in Heart Failure and Annual Scientific Meetings Fri 10/9 - Sun 10/11 in Phoenix
🤖 Made with AI
Cardiosense is at ACEP26 in Chicago, Oct 5-7. Find us at booth #2516 at McCormick Place. 🫀
That's a wrap on UCSF's Hearts in Sonoma.
A big one for us as the CardioTag™ device was demoed on a patient in front of a packed room. Great way to close out the weekend!
📍 Next stop: ACEP26, Oct 5-7 in Chicago. Find us at booth # 2516.
We're headed to UCSF's Hearts in Sonoma Sept 25-26.
Catch our team at the exhibitor tables and don't miss the live CardioTag™ demo during 'Cool Tools in Clinic' session. 🫀
📍'Cool Tools in Clinic' - Sat 9/26 @ 10:35am PT
ucsf.cloud-cme.com/course/co…
🎉 We're proud to share that Cardiosense has been named one of TIME's World's Top HealthTech Companies of 2026!
Congrats to our team, clinical partners, and everyone that's supported our journey!🫀
Read more: time.com/article/2026/09/16/…
Our CMO Dr. John Martin talks UT Southwestern and bringing CardioTag™ to market to help transform heart failure care. 🫀
Read his Alumni Spotlight: engage.utsouthwestern.edu/wh…
Cardiac filling pressure can now be accessed noninvasively!
For the first time ever, FDA-authorized AI can provide critical hemodynamic information without a right-heart catheterization or implanted sensor.
→ Read how we got here: cardiosense.com/2026/08/desi…
🚀 Breakthrough medical AI only matters if patients can access it.
Our latest blog explores how CMS’s proposed SaMS framework could support access to algorithm-driven technologies—including Cardiosense’s CardioTag™ device.
🔗 Read more: cardiosense.com/2026/07/clos…
Cardiosense is proud to support the 2026 Duke Heart Failure Symposium.
Come visit our exhibit to learn how noninvasive cardiac filling pressure could support heart failure management workflows.
📍 Durham Convention Center
📅 June 6, 2026
🤖 Made with AI
We’re thrilled to announce we've received De Novo classification from the U.S. FDA for PCWP Analysis Software, the first AI algorithm to noninvasively provide pulmonary capillary wedge pressure (PCWP) readings for patients w/ heart failure. Read more: bit.ly/3RwF1bK
We’re excited to see our CMO, John Martin, MD, speaking at #ACC26!
🫀 Session 8006: Emerging Sensors & Technologies in CV Medicine
📅 March 29 | ⏰ 9:30–10:30 AM CT
📍 Future Hub (Exhibit Hall)
Join the conversation on the future of cardiovascular innovation.
🤖 Made with AI
Amit Gupta, Co-founder & Chief Strategy Officer at Cardiosense, takes the stage at the Chicago Hemodynamic Forum. He joined clinicians and researchers to share how AI-driven, noninvasive hemodynamic monitoring has the potential to transform heart failure management.
New at #AHA2025: Cardiosense collaborator @FudimMarat (@DukeHealth) presents a new analysis of SEISMIC-HF I showing how AI-enabled PCWP assessment has the potential to aid providers in rapidly assessing hemodynamic congestion.
📍Clinical Science Zone 2
🗓️ Nov 8 | 🕛 12:15 p.m.
New from #TCT2025: Dr. Anjan Tibrewala presented new insights from SEISMIC-HF I highlighting the potential that noninvasive hemodynamic assessment could offer in helping clinicians optimize treatment for hospitalized heart failure patients. 🔗 apnews.com/press-release/bus…
New at #TCT2025: Dr. Anjan Tibrewala (@Northwestern) will share new SEISMIC-HF I data on AI-enabled volume assessment in heart failure using the FDA-cleared CardioTag™. Join us on 10/26 to hear the presentation and explore noninvasive, pressure-guided cardiac disease management.
Thrilled to be featured by @GeorgiaTech Commercialization. The article underscores the years-long journey to translate foundational science behind the CardioTag™ device into a new clinical tool for cardiovascular care. Discover more🔗commercialization.gatech.edu…
Cardiosense CMO Dr. John Martin takes the stage at @HFSA to share how we’re making noninvasive, hemodynamic-guided heart failure management a reality for patients everywhere. Connecting with fellow clinicians reinforced the need & impact of advancing hemodynamic-guided care.
